With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Industries included in the sector are electrical equipment and industrial machinery.

Fortune Sector Leaders: Industrials

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Industrials came out on top this year, with 22 companies featured on the list.

100 Fastest-Growing Companies

This year’s Fortune 500 marks the 68th running of the list.

This year’s Fortune 500 marks the 67th running of the list.

This year's Fortune 500 marks the 66th running of the list.

This year's Fortune 500 marks the 65th running of the list.

This year's Fortune 500 marks the 64th running of the list.

Fastest-growing Companies

Revenue 3 Yr Growth Rank

Revenue 3 Yr Annual Growth Rate

EPS 3 Yr Growth Rank

EPS 3 Yr Annual Growth Rate

Total Return 3 Yr Rank

Total Return 3 Yr Annual Rate

Beat S&P 500 3 Yr Return

Current Streak

Years on List

Sector

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Ingersoll Rand traces its roots to 1871, when inventor Simon Ingersoll introduced a steam-powered rock drill that helped reshape mining and construction. In parallel, Gardner Denver, founded in 1859, built a legacy in compressors and flow-control technologies. In 2020, Gardner Denver merged with the Ingersoll Rand Industrial segment to form today’s Ingersoll Rand. Today, the company is headquartered in Davidson, N.C., with roughly 21,000 employees serving customers across the globe providing mission-critical flow creation and life sciences and industrial solutions.

Q3 2026

Q2 2026

Q1 2026

Ingersoll Rand (IR): Company Profile, Stock Price, News, Rankings

legacy

Ingersoll Rand

ingersoll rand

Hello, everyone. Thank you for joining us, and welcome to Ingersoll Rand's third quarter 2026 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Max Vorcheimer, Director of Investor Relations. Max, please go ahead.

Thank you for joining Ingersoll Rand's Third Quarter 2026 Earnings Call. I am Max Vorcheimer, Director of Investor Relations, and joining me this morning are Vicente Reynal, our Chairman and CEO, and Vik Kini, our Chief Financial Officer. Our earnings release and presentation were issued yesterday afternoon and are available on the Investor Relations section of our website, where a replay of this call will also be posted. Before we begin, please note that today's discussion will include forward-looking statements subject to the risks and uncertainties described in our SEC filings and on slide two of this presentation, which you should read in conjunction with the information provided on this call.

We will also reference certain non-GAAP financial measures. Reconciliations to the most comparable GAAP financial measures are included in our earnings release and this presentation, both of which are available on the Investor Relations section of our website. Today, we will review our third quarter results, discuss segment performance, and provide an update to our full year 2026 guidance. During Q&A, please limit yourself to one question and one follow-up to allow time for other participants. With that, I will turn the call over to Vicente.

Thanks, Max, and good morning to everyone, and thank you for joining today. Beginning on slide three, we delivered robust financial performance in the third quarter, highlighted by 18% organic orders growth, 4% organic revenue growth, and a 17% year-over-year increase in adjusted EPS, excluding the benefit of IEEPA tariff refunds received during the quarter. Organic orders growth accelerated across both short-to-medium cycle and long-cycle businesses, including a particularly large engineered-to-order solution win that we will discuss in more detail shortly. Important to know that excluding these ETO order, organic orders still grew high single digits. As we will discuss this morning, we are raising our full-year revenue and adjusted EPS guidance. The board has also authorized a $2 billion increase to our share repurchase program, providing greater flexibility to compound shareholder value.

M&A continues to be our top priority for capital deployment, supported by a robust pipeline of attractive strategic bolt-on opportunities. We're excited about the momentum we're building, including another acquisition that we successfully closed this morning, which I will look forward to sharing more about in a moment. Turning to slide four, underpinning our performance is IRX, or Ingersoll Rand Execution Excellence. IRX remains our key enabler of execution, and it is how our teams around the world stay focused on controlling what we can control, supporting our customers, driving productivity, and allocating capital effectively. A key strategic imperative of the IRX process, as you can see on this slide, is to deploy talent. Earlier this morning, we announced new leadership appointments. Scott Watson, who was previously leading our Life Science business, has been named Senior Vice President and Group President of ITS North America and ITS EMEIA.

Shaun Carlson, who was previously leading our Precision Technology business, has been named Senior Vice President and Group President of the PST segment. These appointments reflect the growth of our businesses and the depth of our leadership bench. Their leadership in these roles will position us to move faster, execute with greater focus, and better serve our customers. I also want to recognize Mike Weatherred, who will transition to an advisory role through May 2028 before retiring. A longtime member of our leadership team, Mike helped drive IRX adoption across the company, where it is now very firmly embedded in our culture. We thank him for his many contributions and wish him well in his next chapter. Turning to slide five, I am pleased to share that this morning, we closed on the acquisition of IVEK Corporation, a leading provider of small-volume precision liquid metering and dispensing systems.

The business adds approximately $40 million in annual revenue and will sit within our PST segment, specifically in the Life Science business. It expands our expertise in key precision pump technologies and strengthens our solution for Life Science customers, and was acquired at a low double-digit multiple consistent with our disciplined valuation standards. Year-to-date, we have closed or signed eight transactions, and we have an additional seven transactions at the LOI stage. Our funnel remains healthy, with more than 200 companies, and approximately 90% of our deals continue to be internally sourced.

For 2026, we now expect to be approximately 200 basis points-300 basis points of annualized inorganic revenue. Our 400 basis point-500 basis point target is an average over the cycle and not a single-year goal, and it remains unchanged. This year simply reflects transaction timing, not any change in our strategy or the strength of our funnel. Our disciplined M&A strategy remains a key differentiator and an important driver of long-term value creation. Now, I will hand it over to Vik, who will review our financial performance.

Thanks, Vicente. Starting on slide six, the third quarter was a strong quarter of execution. Orders finished at $2.35 billion, up 21% year-over-year, with organic orders up 18%. Book-to-bill finished at 1.14x, well above what we typically see in the third quarter, with the pickup in short-to-medium cycle business coupled with long-cycle project bookings improving meaningfully. Revenue grew 6% year-over-year to $2.1 billion, with organic revenue growth of 4%. Aftermarket revenue represented 36% of total revenue during the quarter and continues to be an important contributor to the resiliency of our portfolio. Important to note, aftermarket grew mid-single digits in Q3. Adjusted EBITDA was $584 million. This includes $32 million of IEEPA tariff refunds received in the quarter, $25 million in ITS, and $7 million of PST.

Excluding those refunds, adjusted EBITDA was $552 million, up 1% year-over-year, with a margin of 26.7%. The year-over-year margin decline was driven primarily by the known inflationary pressures and pricing dynamic in China. Importantly, margins improved meaningfully on a sequential basis, up 130 basis points from Q2, excluding tariff refunds, consistent with what we outlined last quarter. Unallocated corporate costs were $44 million in the quarter, and we continue to expect approximately $170 million for the full year. Notably, our adjusted tax rate for the quarter was approximately 17%. We have been simplifying our global legal entity structure since the 2020 merger, aligning it with how we operate the business. Through strong planning and execution, we are able to now use foreign tax credits we previously could not, which drove a discrete benefit in Q3.

We expect these changes to provide a durable benefit to our tax rate and cash repatriation efforts going forward. As you will see in our updated guidance, we now expect a full-year adjusted tax rate of approximately 20%. Adjusted EPS was $1.07 for the quarter, and excluding IEEPA tariff refunds in Q3, adjusted EPS was $1.01, up 17% year-over-year. Turning to slide seven, free cash flow for the quarter was $623 million, which includes $162.5 million of ILC Dover transaction-related recoveries collected in the quarter. Excluding those recoveries, free cash flow was approximately $461 million, up roughly 40% year-over-year. We ended the quarter with approximately $3.9 billion of total available liquidity, including approximately $1.3 billion of cash and $2.6 billion of available revolving credit facility capacity.

Leverage improved to 1.6x, down from 1.7x last quarter and 1.8x a year ago. During the quarter, we deployed $90 million towards acquisitions and returned $358 million to shareholders through $350 million of share repurchases and our quarterly dividend. As Vicente noted, the board authorized a $2 billion increase to our share repurchase program, incremental to the $313 million remaining under the existing authorization. This gives us flexibility for additional opportunistic repurchases over the short and medium term, while M&A remains our first priority. Our balance sheet remains a strategic asset, and this authorization does not change our ability to execute on the acquisition funnel. As an update on the ILC Dover transaction, last quarter, we announced an initial recovery of $187.5 million.

Since then, we have reached a series of additional settlement agreements that brings total gross recoveries to approximately $425.1 million. We collected $25 million in Q2 and $162.5 million in Q3, and we expect to collect the remainder of the recoveries in the fourth quarter. Consistent with our focus on earnings quality, these recoveries are excluded from adjusted earnings. We are very pleased with the final outcome of the recovery process with respect to the ILC Dover transaction and intend to use the proceeds in line with our capital allocation strategy. I'll now turn the call back to Vicente to discuss our segment performance.

Thanks, Vik. Turning to slide eight, ITS delivered a strong quarter. Orders increased 25% year-over-year, including 22% organic growth, resulting in a book-to-bill of 1.17x. Organic orders were driven by continued momentum in the short-to-medium cycle businesses, as well as a significant pickup in long-cycle activities. On our last call, we noted the acceleration in long-cycle bookings during the first four weeks of July. That momentum held throughout the quarter, and later in the period, we booked an approximately $195 million order that is an engineered-to-order solution for mission-critical data center infrastructure. This order covers integrated backup power solutions for mission-critical data center operations, paired with a differentiated filtration system engineered to the customer specifications for maximum uptime, longevity, and reliability. Let me give you some further color on how we have positioned ourselves to enter new growing markets, and data center is just one example.

We're taking technologies proven in demanding industrial applications and bring them to a new end market. Several companies we have acquired in recent years had power generation and thermal management capabilities that historically served industrial customers, and we were able to adapt them very quickly for data centers. We're getting faster at combining technologies from across our portfolio into differentiated solutions that competitors cannot easily copy. We also win on engineering depth and extensive network of service technicians. Let me walk through the economics of this large order. This order is accretive to EBITDA dollars and adjusted EPS from the start. As we ramp, we're investing in dedicated capacity, engineering resources, and supplier qualification, so initial shipments will carry margins below our company average. That's a deliberate choice. We're investing now to secure a position in a fast-moving market where speed and reliability decide who wins.

IRX gives us a proven playbook to drive productivity, pricing discipline, and aftermarket pull-through as volumes scale. We expect margins to move towards portfolio levels as the ramp matures and additional orders follow. Revenue in this order will convert over the coming quarters, most meaningfully in 2027, and we expect future orders in this space to be a bit lumpy. Our entry into data centers show how IRX let us move fast and win in new markets. A year ago, we had no presence here, and in less than 12 months, we have built a sizable funnel and established partnerships with several customers. That did not happen by chance. With the massive investment flowing into data centers, we have been deliberate about looking across our portfolio and bringing our unique capabilities together for this end market. Our technology breadth gives us a clear competitive advantage.

We combine power generation, thermal management, including chillers and water cooling pumping skids, and other critical flow technologies, leveraging our proven legacy portfolio and acquired innovations. Combined with our global engineered-to-order capabilities, that lets us deliver complete customized solutions faster than customers can get them elsewhere, which positions us to capture profitable share in these markets. I would like to also highlight that excluding this award, ITS organic orders were up high single digits, and long-cycle organic orders were up over 20% in the quarter, building solid backlog for 2027. Revenue increased 5% year-over-year, including organic growth of 4%, with all regions contributing positive organic revenue growth for the second consecutive quarter. ITS adjusted EBITDA, excluding IEEPA tariff refunds, was $451 million, with a 27.8% margin, down 120 basis points year-over-year, driven primarily by known inflationary pressures and the China pricing dynamics noted earlier.

Margins rose 100 basis points sequentially from Q2 as price cost continues to improve. Over time, we still believe that the ITS business, outside of the data center ramp we just discussed, has the right to play in the 30%-40% incremental margin range, and we believe the current pressures are transitory. For our innovation in action highlight, we're showcasing our new line of oil-free rotary screw compressors, redesigned for world-class energy efficiency performance and reliability, including a new rotor design and an optimized cooling jacket. Advanced sensor technology transmits real-time operating data to the Ingersoll Rand service network, enabling proactive monitoring and maintenance. That connectivity supports our customers' uptime and also strengthens our aftermarket and recurring revenue opportunity over the life of the install base. Turning to slide nine, PST delivered another excellent quarter and continues to demonstrate the strength of the platform we have built.

Orders increased 7% year-over-year, including 4% organic growth, with a book-to-bill of 1.01x. Revenue increased 7%, including 6% organic growth. Life Science Technologies continue to deliver solid momentum, with low double-digit growth in both orders and revenue. Excluding IEEPA tariff refunds, adjusted EBITDA was $145 million, with a 32.6% margin, up 180 basis points year-over-year and 110 basis points sequentially. Margins expanded in both Precision Technology and Life Science Technologies, reflecting strong execution and continued IRX benefits. We're pleased with the PST sustained margin improvement, including five consecutive quarters of incremental margins above 40%. For our innovation in action, we're highlighting YZ Systems Zero Emission Odorization, or ZEO platform. Gas odorization is a critical safety requirement that ensures communities have a safe supply of natural gas.

ZEO incorporates a Milton Roy electric pump to dramatically reduce utility companies' carbon footprint across a pipeline network, and an average-sized utility can reduce methane emissions by up to 15 million cubic feet per year using this next-generation platform. It is a great example of commercial synergy across our brands and how our portfolio supports mission-critical infrastructure. Turning to slide 10, given our performance through the first nine months, today we are updating our full-year guidance. Starting with revenue, we now expect revenue growth for the year to be in the range of 5.5% and 7%. The increase in outlook is driven by an increase in organic growth expectations, now expected between 2%-3.5% for the year. We continue to expect approximately 2.5% growth from M&A and approximately 1% from FX. Our adjusted EBITDA guidance, excluding Q3 IEEPA tariff refunds, is unchanged at $2.13 billion-$2.19 billion.

Despite ongoing inflationary pressures and challenging pricing environment in China, we are holding our range. We currently expect to finish at the bottom half of the range. Our corporate cost estimate remains on track at approximately $170 million for the year. We are raising adjusted EPS, excluding Q3 IEEPA tariff refunds, to $3.58-$3.70. The increase is driven primarily by a lower adjusted tax rate, now approximately at 20%, and a lower share count of approximately 390.5 million, reflecting our year-to-date repurchases. Net interest expenses is still expected to finish at approximately $230 million. For free cash flow, we now expect to deliver more than 100% conversion of adjusted net income, including the ILC Dover-related recoveries. Our underlying operational free cash flow conversion remains unchanged at approximately 95%. Our CapEx forecast remains at approximately 2% of sales.

Finally, on slide 11, as we continue this portion of the call, I am encouraged by the momentum we are seeing across the business. Demand continues to improve across both short and long cycle activity. Our teams continue to execute at a high level, and our M&A pipeline remains very robust. In a complex global environment, we continue to stay nimble, leveraging our in-region for region manufacturing footprint and pivoting quickly toward the most attractive end markets. Our strong balance sheet, ample liquidity, and expanded repurchase authorization gives us significant flexibility to keep executing on our disciplined capital allocation strategy, which compounds earnings and delivers durable value creation for shareholders. IRX remains the backbone of our organization and continues to enable execution and outperformance across the company.

With a 1.14x book-to-bill and a growing long cycle backlog, we believe we are well-positioned to finish 2026 strong and carry real momentum into 2027. Finally, and most importantly, I want to thank you, our employees around the world, for their continued commitment, dedication, and ownership mindset. Your efforts continue to drive our success and help us deliver strong results for all the stakeholders. With that, I will turn the call back to the operator and open the line for questions.

We will now begin the question-and-answer session. Please limit yourself to one question and one follow-up. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Mike Halloran with Baird. Your line is now open. Please go ahead.

Maybe we just start on where you were ending there, Vicente, on the momentum you are seeing across the portfolio. Maybe just dig a little deeper on end markets, geographies, where you are seeing the most success right now. Any areas or pockets where you haven't seen that recovery curve materialize, and then obviously the sustainability as we move into next year?

Yeah, Mike, I'll say that we're very encouraged by the global momentum we're seeing across basically all the regions. So, if I take, for example, ITS, let me break that by each of the respective regions. Americas, on the order side, Americas was up mid-single digits. EMEIA was up low 20s, which included a very nice acceleration on some long-cycle projects. Asia Pacific, X that large data center, which it is for Asia Pacific, outside of China, was definitely up also low single digits. So, you can see that the momentum we saw really well into most of all the regions. From an end market perspective, I'll say anything related to food, beverage, the more core fundamental end markets that we have always played into, we're seeing better momentum across all of them.

I would say nothing in particularly that I would categorize as negative, except the kind of known things such as, for example, electric vehicle and also renewable natural gas. Those are kind of end markets that have been kind of down and flattish here for now quite some time, but we are not seeing pickup. In terms of kind of fundamental, mostly food, beverage, I mean, clearly biopharma with the Life Sciences businesses that you saw, power generation, wastewater, some nuclear exposure too as well. That is where we are seeing good momentum now.

No, that is helpful. Then on the margin side, maybe just talk through kind of the two components. First, the Chinese pricing. When do you think you start lapping that? Any signs of change there, at least stability? Then secondarily, on the price cost side, when do you think your margin and/or EBITDA dollar neutral? Just some updated thoughts there, please. Thank you.

Yeah, sure, Mike. I will take that one. I will start with your last question on the price cost side. On the price cost side, I think we continue to be encouraged by kind of the momentum we are seeing. Fair to say here that in Q3, price cost was slightly dollar positive, but obviously still a margin headwind. That being said, I think as we said in our last quarter call, we have been taking the requisite actions through the course of the year, and we did see, I would say, some sequential improvement from Q2 now into Q3 and the back half of the year, which I think was a strong catalyst, obviously, of the sequential margin expansion you saw across the enterprise, and particularly on the ITS side.

I think our view as we continue to move forward is that equation will continue to improve as we move through the balance of the year, but really into 2027. Then on the China side of the equation, similar. I would not say anything has dramatically changed there. We acknowledge that China still is a headwind from the pricing perspective in a very comparable range to what you saw in Q2. But we would acknowledge here that things are largely stabilizing in that respect from the levels we saw kind of exiting Q2. We would expect that we will be lapping that really as we get through kind of by the first half of next year.

Your next question comes from the line of Nigel Coe with Wolfe Research. Your line is open. Please go ahead.

Yeah. Good morning. First of all, congratulations on the large data center order. I just want to make sure that you are competing here against the likes of Carrier, Trane, the traditional chiller manufacturers. I just want to make sure that is the case. Then obviously, X this one order, high single digit, 9% order growth. If we took out other large orders in the larger compressor orders, how would you characterize the growth in the small, medium-sized compressors? Then, Vik, just maybe just clarify on this $195 million order, that will be kind of accounted for over time, percentage completion accounting on that order? Thanks.

Yeah. Nigel, on the first question around some of the data center capabilities, I will talk more about what is more unique and differentiated on what we are doing. I think we are playing here across both power and thermal management with technologies that can be more holistically put together. As you have known, we do a very good sizable of our businesses engineered-to-order solutions, and that is the area where we believe we have a competitive advantage. The ability to be able to create a combined engineered-to-order mission critical, where there is high density, low footprint, modularity, and be able to kind of ship it to the location so you can do a plug and play.

That is a unique capability that we have, that we have been utilizing in other end markets, and now that we are kind of leveraging the power of the technologies that we have and creating some unique solutions. I think that is more on where I will say we have a competitive advantage. On the second question around the high single digit. Last quarter, as you remember, we reported low to mid-single digit order growth in short to medium cycle, and this quarter, we were squarely in the mid-single digit range. That tells you that we continue to see that sequential acceleration and some very good momentum here.

I would say this was due to a continued broad-based industrial improvement, as we just kind of said, as well as that strong execution by our teams in the equipment that it was basically up low double digit outpacing aftermarket, although aftermarket was still also high or positive in the kind of mid-single digits. So, again, we're even excluding anything else, I mean, we still see both short cycle, short to medium cycle, as well as long cycle momentum here.

Yeah, Nigel, on your question regarding the revenue cadence, the accounting treatment, yes, to answer your question, this will be, the $195 million order will be POC with the majority expected to be kind of consumed or digested through the course of 2027.

That's great. I know I had three questions there, so if I can just have a quick follow-on. Really nice momentum, sequential momentum in ITS margins in 3Q. Just based on your commentary around the EBITDA for the full year, what should we expect for ITS margins in 4Q? Thank you.

Yeah, Nigel, I'll take that one. So, I think the simplest way to think about Q4 is we expect to see essentially a similar level of sequential improvement from Q3 to Q4, as you saw from Q2 to Q3, so approximately 100 basis points. I would point to a lot of the same drivers that we've called out before. I'd say slightly improving price-cost equation, the Q4 volume that sequentially continues into Q4. Obviously, Q4 is typically our strongest volume from a quarter from a seasonality perspective. Then obviously, the productivity equation would generally follow that, whether it be the classical procurement side or some of the i2V type initiatives. So, very similar, I'd say, drivers, but comparable margin expansion sequentially in Q4.

Your next question comes from the line of Steve Volkmann with Jefferies. Your line is now open. Please go ahead.

Good morning, guys. Thank you for taking the question. Back to the big $195 million order, how should we think about that sort of more medium term? Is there a funnel of additional orders that could be similar, and would you be surprised if we didn't have more of these to talk about a year from now?

Yeah, Steve, I will say that the funnel is fairly substantial and robust. I mean, I think about a year ago, we were not playing in this end market. We obviously structured ourselves, hand-selected a few team members, and over the past 12 months, that's what we've been able. Been able to talk to a lot of hyperscalers, co-locators, and understand the voice of customer in terms of what's needed and what's missing, and that's where we're playing right now. Basically, fulfilling those critical needs that are today, in some ways, unmet. So yeah, funnel is growing and continues to accelerate.

Okay. My follow-on, I guess, Vicente, is how do you sort of manage this from a top-down perspective? What I mean is that there's a lot of angst around sort of the rate and cadence of data center spending and lots of views around what that's going to look like. You're allocating some capital, building out some supply chain, et cetera. Is this a risk if things don't come out the way you think they should, or can you somehow sort of this variable?

Great question, Steve. I think the beauty of this one here is that we're taking products that we have in our portfolio that are actually widely used in the industrial landscape based on current solutions that we have. I think if later down the road some of these data center volume kind of goes down, we still have the product that we're selling into industrial space. So, in terms of incremental CapEx and OpEx, just think about it from a CapEx perspective. We're still going to be well within our 2% of sales on that CapEx.

So, I think we're a low CapEx intensity, and we're being very thoughtful in the places that we play. We're not going super broad-based. We're going very focused on some specific customers. We've done a lot of customer segmentation, and we're selecting either one, call it a few hand-selected hyperscalers as well as co-locators, and that's basically we're very focused on deep customer relationship.

Okay. I appreciate it. I will pass it on.

Your next question comes from the line of Rob Wertheimer with Melius Research. Your line is open. Please go ahead.

Thank you. Good morning. I had a quick clarification on the data center. Is that a framework kind of agreement, or is that specific to one site where you might see other sites of similar scope?

Wow. Okay, perfect. Vicente, this is a little bit of a bigger picture one, but you think about AI's impact across biopharma, and there's already some glimmerings of new drug discovery, new applications, all sorts of things that are changing faster than we're used to. If you look ahead a few years, do you see this as a thing that changes your opportunity in this space? Do you see any momentum there? Maybe just talk about how that world is changing. Thank you.

Yeah. Great question, Rob. As you have seen, we have been investing in lab automation. We made an acquisition with Scinomix, but also inside our business, we have another company called Zinsser Analytic. Those are companies that basically do robotic automation for drug discovery. We are participant of developing this machinery and actually providing this robotic automation to customers that are leveraging AI to actually create recipe for personalization of medicine, particularly in the immunotherapies. Yes. We think that as more customers continue to use AI and they continue to do this personalization, whether immunotherapy, therapies, or other things that require some mixing of different compounds, that is going to be actually a very good play for us moving forward.

Your next question comes from the line of Nathan Jones with Stifel. Your line is open. Please go ahead.

I guess I'll ask one on the PST side. You mentioned five consecutive quarters with incrementals above 40%. Is that kind of the way we should be thinking about, I don't know, the next five quarters? And longer term, how we should think about the path back to the targeted 35% margin level?

Yeah, Nathan, I'll take that one. We've always talked about the PST business being one that obviously it's a higher margin profile business, and you clearly are now seeing, I think, the benefits of, I'd say, solid pricing momentum, but obviously the volume, particularly led by areas like biopharma, like Vicente just mentioned. So, I think now, obviously, with a well-integrated segment between the two platforms we have with Precision Technologies and Life Sciences, yes, we think that this is one that with, I'd say, the kind of normal growth algorithm executing towards that 40% type incrementals is kind of where this business wants to operate.

And to your point here, we've now solidly been above, well, above 30% EBITDA margins here for several quarters, executing in that now above 32% range here in Q3, with expectations to be in a similar range here in Q4. I think our exit momentum is quite solid, and clearly the mid-30s kind of EBITDA target range that we'd put out is, I'd say, well within sight.

Okay. I'm going to ask about the same question that I asked Vicente on every call about quote to order times. Obviously, you've seen an improvement in momentum here in orders. You're talking about strengthening in end markets. Are you seeing that quote to order time start to shrink, or are customers still fairly hesitant on pulling the trigger?

I mean, I'd say we're definitely seeing a better momentum and acceleration through the process. I don't say it's back to normal levels, but clearly we're encouraged by the decision-making improvement. But quote to order cycle, I'd say they have not shortened meaningfully. Improving, I will say, projects getting to the finish line, yes. Definitely we're not seeing cancellations. And I think the most important leading indicator here that we're tracking really extensive across the entire company is the number and obviously dollar amount of RFQs, so requests for quotes and requests for pricing. So these are customers trying to get a preliminary pricing on specific projects, and that we're definitely seeing rapid acceleration.

Your next question comes from the line of Joe O'Dea with Vertical Research. Your line is now open. Please go ahead.

I will start on the data center topic, but could you just go through a little bit the process that you went through for adapting the technologies you have for data centers and expand on what you do internally, what technologies you use from partners? Did you need to establish some new partnerships in doing this? Then just regionally, do you have some advantages in Asia, or what about the U.S. as an opportunity for you, just given the size of the market there?

Yeah. We're taking technologies from companies that over the past few years we have acquired around thermal management and also combining our ability of developing very quick engineered-to-order skid solutions. They could be skids for filtration, it could be skids for moving liquids and fluids. That's core of what we have done for many, many, many years. I think what's very unique here is how we took the approach of basically, I personally spent a lot of time with a hand-selected group of teams on a global basis to go out and really understand what were the meaningful gaps that were not being offered to some of these customers, and then now we're going back into the kind of regional execution as we always do.

In this case, started with Asia Pacific because in Asia Pacific, we had a bit more experience around that kind of power management and some thermal management solutions, and that's really why I started in Asia Pacific. Clearly, the U.S., we're seeing now, as we always do. I mean, we typically start in one region, and then we start kind of piloting that, and then we move into the other region, similar to what we have done in the historical with CARE solutions or recurring revenue, right? In this case, for data centers, we started in Asia Pacific, and now we're moving globally. About six, nine months ago, then we kind of came to the U.S. and with a very similar approach and solutions, and now we're seeing good momentum there.

The last area of focus for us too as well has now started to be is India, where I was there, we were there a few weeks ago, and we're seeing some rapid acceleration. Again, taking the same solutions that we develop in Asia Pacific and moving them to the other specific regions to offer something similar to the needs that are out there. In terms of partnerships, I mean, for the most part, this is not too dissimilar to what we do in our engineered-to-order solutions. We always have a very good solid supply chain, and we're leveraging that supply chain to really create what we're creating here. Specific kind of signed partnerships and things of that nature, nothing that I would call out. Yeah.

Got it. That's great. Just a near-term one, when we think about growth into the end of the year, the full year range gives pretty wide range of outcomes for fourth quarter organic. I mean, is it a base case where the comp does get a little bit tougher, but there's some demand acceleration? Can you do a pretty similar level of organic growth in Q4 as you did in Q3, pretty similar between the segments? Just any color you're willing to provide there.

Yeah, Joe, I will take that one. I think you are spot on here in the context stuff. Obviously, Q4 has a little bit more of a meaningful comp on a year-over-year basis. I think the way to think about Q4 is, right now, expectation is in the 2%+ kind of range for the total company on an organic basis, and actually both segments looking fairly comparable. That is kind of the expectation at this point in time, but I think as you have seen us before here, if there is opportunity to obviously outperform that, clearly, we will continue to execute. But, I think that is probably the right way to think about Q4 based on the guide at this point in time.

Your next question comes from the line of Joe Ritchie with Goldman Sachs. Your line is now open. Please go ahead.

I'm curious on the margin profile of this order, the data center order. It sounds like you're using a solution that you've used previously, you've sold these types of products before. Is the fact that it is kind of diluted to the portfolio margins a function of the investments that you're making? Is this type of solution typically diluted? I just want to, if there's any way to kind of level set the margin profile of this particular award, that would be great.

Yeah, sure, Joe. Think about it similar to sometimes when we do an M&A, that typically, as we bring in M&A, it kind of comes in the kind of 20s, and then obviously we ramp it up to fleet average over the course of the medium term. So, I think it's very similar here. Obviously, this is all organic, but the investments in some of the OpEx that is needed to kind of do this ramp, it comes in at that kind of level, so it starts to be in that low 20s, and then obviously fairly quickly as we start seeing more incremental volume as well as the continued execution of the output, this business can get to that fleet average that we have.

Got it. That's helpful context, Vicente. Sounds like the demand environment, even outside of this award, has been pretty healthy. I'm curious if you're willing to comment on October trends, and how things have started so far this quarter.

Yeah, Joe. No comment on October. I think last quarter we were commenting on July just because it was a unique moment in time. I will say things continue to be healthy. We're seeing healthy demand broad-based on a global basis, and we're just encouraged with how the teams continue to execute and are seeing some of the wins.

Your next question comes from the line of Andy Kaplowitz with Citi. Your line is now open. Please go ahead.

Vicente, I know you said transaction timing around M&A has been a bit more difficult this year, but with the financial metrics you want to get, can you get what you need here? It seems like you're laddering into repurchases a bit more, so in terms of your priorities around capital deployment, are you adapting a bit to sort of the current environment?

No, Andy. I think M&A continues to be that priority. I think we continue, we're very disciplined buyers, so we remain disciplined, and in terms of the funnel continues to be over 200 companies and very active. I think is nothing that we're worried about M&A flywheel at all. I think in some respects, we're very, very encouraged with what we're seeing here on the M&A front, and it's just basically a matter of year timing. Nothing to worry about.

Great. Can you give a little more color into what you're seeing in PST in the near term? I think your order comps were more difficult in Q3 than Q2, but growth seemed to stay strong, at least on the Life Sciences side of the business. So, maybe just comment on the durability of the order and revenue strength you're seeing in PST.

Yeah, Andy, I'll take that one. I think we continue to be really encouraged by what we're seeing in PST. I think as we mentioned here, Life Sciences orders were up low double digits on an organic basis, which I think continues to speak to the strength in just kind of the Life Sciences kind of platform and kind of the trends that Vicente mentioned earlier. On the Precision Technology side, obviously, when you look at the total and you see low single, low double digits for our Life Sciences, there was a slight headwind on the overall Precision Technology orders, which was really driven, I would say, by just the timing of some of our long-cycle pump projects, which was down roughly mid-single digits.

When you actually look at the, what I'll call more short to medium cycle kind of core pump business within precision technologies, that grew low single digits on an organic basis. So, again, I think it speaks to, I'd say the durability of what we're seeing. To your point here, I think the strength in the orders profile that we've seen over the last few quarters is translating nice to revenue, and you see obviously the margins going with it. So again, we'll spare any commentary on 2027 guidance at this point in time, but I think we continue to feel encouraged by the momentum we're seeing and the kind of the exit we're seeing here to the balance of the year.

Your next question comes from the line of Nicole DeBlase with Deutsche Bank. Your line is now open. Please go ahead.

Ingersoll Rand (IR) Q3 2026 Earnings Call Transcript

Company Participants